Schizophrenia is a severe mental disorder characterized by disturbances in cognition, emotion, and behavior that poses a severe emotional and economic burden on society. Individuals with schizophrenia often have difficulty coping with daily demands of life, culminating in poor vocational and occupational attainment and social function (functional outcome). Currently available treatments are able to manage some of symptoms of schizophrenia, but often fail to improve functional outcome. The development of therapeutic interventions capable of addressing outcome in schizophrenia would constitute a major breakthrough in the treatment of schizophrenia and would help to ease the burden this disease places on individuals, families, and society. The lack of therapeutic agents capable of addressing poor functional outcome is likely due to the difficulty in developing preclinical models that accurately encapsulate the factors that lead to poor functional outcome, limiting the ability to develop putative therapeutic agents for improving outcome. To date, little is known about which aspects of schizophrenia most strongly contribute to determining outcome. Low IQ, and poor pre-morbid function may be moderately related (Brill et al., 2009; Leeson et al., 2009), while the presence of negative symptoms and poor cognition appear to be more strongly related to functional outcome (Green, 1996; Milev et al., 2005), none of which are easily addressed in translational animal models.